UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Compare retirement index funds to see which has the lowest fees while meeting your risk and diversification goals.
28,038 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Intel staged a monster rally, narrowing the gap with AMD. This article breaks down what the surge means for investors...
Debt service now approaches $1 trillion annually as the interest on the $38.8 trillion national debt climbs, squeezin...
The Jets ETF has breached critical chart support, suggesting airline stocks face risks beyond rising fuel costs. Tech...
A seasoned investor at Benchmark warns that the AI boom may be inflating prices beyond fundamentals, signaling a comi...
CrossCountry Mortgage pushes back in the bid for Two Harbors, saying a fully financed cash offer backed by Citi will ...
Caesars Entertainment moves to go private in a $17.6 billion deal, and investors are eyeing four lagging U.S. compani...
Strategy Inc. disclosed a fresh BTC purchase, increasing its digital asset reserve to 818,334 coins worth about $54 b...
XRP would need a dramatic rally and strong regulatory clarity to reach $20 this cycle. This report weighs the math, t...
XRP trades around $1.15 as Ripple builds regulatory momentum and broader adoption. Investors ask if the price underpl...
A sharp, fear-driven decline hit Microsoft, but a deeper look suggests the selloff may reflect sentiment more than so...
Disney has debated separating its Parks division as the media world reshapes itself. This article explains whether a ...